Business - July 4, 2022
Business Q&A: The four Ps of market entry
Patent, pricing, production, and partnerships – these are the four Ps that companies must keep front and center for a successful market entry. Orexo’s CEO Nikolaj Sørensen answers some questions about how his company addressed these aspects when Orexo entered the US market. Although Orexo has successfully entered into the US market, you have been […]
Pharma Business - December 3, 2021
Orexo initiates new development project
Orexo has initiated a new pharmaceutical development project, OX640, a nasal adrenaline product for the emergency treatment of allergic reactions. Adrenaline is commonly used for the emergency treatment of allergic reactions, including anaphylaxis, which is a global and growing health problem. The market is currently dominated by the use of auto-injectors for intramuscular or subcutaneous […]
Clinical Trials - November 16, 2021
Orexo announces positive trial results
Orexo has completed the trial for its lead pharmaceutical pipeline asset, OX124, and the study met its primary endpoints with naloxone exposure within the targeted interval. OX124 showed a significantly faster and higher absorption of naloxone compared to intramuscular dosing with the injection reference product, states the company. A US launch will be initiated in […]
Clinical Trials - July 2, 2021
First patient enrolled in Orexo’s modia trial
The company announces that the first patient has been enrolled in study evaluating the efficacy of digital therapeutic modia in combination with sublingual buprenorphine/ naloxone for the treatment of opioid use disorder. The randomized, open-label, parallel-group study will evaluate whether the use of modia in combination with sublingual buprenorphine/naloxone background therapy is superior to sublingual […]
Intellectual Property - January 5, 2021
Orexo announces new US patent
Orexo has announced that the US Patent and Trademark Office has issued an additional patent for ZUBSOLV, Orexo’s sublingual buprenorphine and naloxone tablet (CII) for the treatment of opioid use disorder. The new patent, US Patent No. 10,874,661, expires in September 2032 and further strengthens the company´s intellectual property for ZUBSOLV in the US. Orexo […]
Agreement - December 10, 2020
Orexo enters license and supply agreement with Accord Healthcare
Orexo has entered into an exclusive licensing agreement with Accord Healthcare, for the commercialization of ZUBSOLV ((buprenorphine (as hydrochloride) and naloxone (as hydrochloride dihydrate)) sublingual tablet. Licensed in Europe, ZUBSOLV is indicated for adults and adolescents over 15 years of age for substitution treatment for opioid drug dependence, within a framework of medical, social and […]
